Hengrui Pharma 恒瑞医药
15 significant filings since 30 May 2026: 10 on buyback and 5 on equity incentive. The latest, on 18 Sep 2026: 恒瑞医药关于首次回购公司A股股份的公告.
自 30 May 2026 起有 15 份重大公告：buyback 10 份、equity incentive 5 份。最新一份（18 Sep 2026）：恒瑞医药关于首次回购公司A股股份的公告。
As of 25 Sep 2026 截至2026年9月25日
Hengrui Pharma 恒瑞医药 is a chemical pharmaceuticals company listed on the Shanghai Stock Exchange since 18 Oct 2000. The company reported revenue of RMB31.63bn in 2025, up 13.0% from RMB27.98bn in 2024, with attributable net profit rising to RMB7.71bn from RMB6.34bn, a 21.7% increase. Profit quality is strong, with operating cash flow per share at RMB1.69 in 2025, ahead of net profit, and a cash flow to profit ratio of 1.46x. Margins remain high, with a gross margin of 86.2% and net margin of 24.4%. The balance sheet is robust, with liabilities to assets at 8.2% and current and quick ratios at 11.68 and 10.98 respectively. In the six months to 30 Jun 2026, revenue declined by 1.9% while profit rose 0.3%. Receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, and segment revenue are not shown.
恒瑞医药是一家化学制药公司，2000年10月18日在上交所上市。2025年营业收入316.29亿元，较2024年279.85亿元增长13.0%；归母净利润77.11亿元，较63.37亿元增长21.7%。盈利质量良好，2025年每股经营现金流1.69元，高于净利润，经营现金流与净利润之比达1.46倍。毛利率86.2%，净利率24.4%，净资产收益率14.3%。截至2026年6月30日，资产负债率8.2%，流动比率11.68，速动比率10.98。2026年上半年营业收入154.56亿元，同比下降1.9%；归母净利润44.65亿元，同比上升0.3%。应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入未列示。
- Revenue growth in the full year 2026 compared to 2025
2026全年营业收入较2025年的同比变化 - Attributable net profit trend in the full year 2026
2026全年归母净利润变动趋势 - Operating cash flow per share in the full year 2026
2026全年每股经营现金流 - Gross and net margins in the full year 2026
2026全年毛利率与净利率 - Liabilities to assets and current ratio as of 31 Dec 2026
截至2026年12月31日的资产负债率与流动比率 - Next dividend announcement and ex-date
下一次分红公告及除权除息日
- Company: Hengrui Pharma 恒瑞医药, Shanghai Stock Exchange 600276; industry Chemical Pharmaceuticals; listed 18 Oct 2000.
公司：恒瑞医药，上海证券交易所 600276；行业：化学制药；上市日期：2000年10月18日。 - Close on 24 Sep 2026 RMB44.86; close on 24 Sep 2025 RMB70.11, RMB69.83 in today's terms; one-year change, adjusted for distributions and share changes -35.8%.
2026年9月24日收盘价44.86元；2025年9月24日收盘价70.11元（前复权69.83元）；一年涨跌幅（复权）-35.8%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB42.67 to RMB71.98.
52周区间（前复权）42.67元至71.98元。 - Market capitalisation RMB297.75bn; P/E TTM 38.5; price to book 4.62x.
总市值2,977.45亿元；市盈率（TTM）38.5；市净率4.62倍。 - Revenue 2025 RMB31.63bn; 2024 RMB27.98bn; change +13.0%.
营业收入2025年316.29亿元；2024年279.85亿元；同比+13.0%。 - Attributable net profit 2025 RMB7.71bn; 2024 RMB6.34bn; change +21.7%.
归属于母公司股东的净利润2025年77.11亿元；2024年63.37亿元；同比+21.7%。 - Net profit excluding non-recurring items, 2025 change +20.0%.
2025年扣除非经常性损益后的净利润同比+20.0%。 - Basic EPS 2025 RMB1.19; 2024 RMB1.00.
基本每股收益2025年1.19元；2024年1.00元。 - Operating cash flow per share 2025 RMB1.69; 2024 RMB1.16; operating cash flow to net profit 1.46x.
每股经营现金流2025年1.69元；2024年1.16元；经营现金流与净利润之比1.46倍。 - 2025 gross margin 86.2%; net margin 24.4%; ROE 14.3%.
2025年毛利率86.2%；净利率24.4%；净资产收益率14.3%。 - At 30 Jun 2026: liabilities to assets 8.2%; current ratio 11.68; quick ratio 10.98; receivable days 59; inventory days 250.
截至2026年6月30日：资产负债率8.2%；流动比率11.68；速动比率10.98；应收账款周转天数59；存货周转天数250。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB15.46bn, change -1.9%; attributable net profit RMB4.47bn, change +0.3%; operating cash flow per share RMB0.30.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入154.56亿元，同比-1.9%；归母净利润44.65亿元，同比+0.3%；每股经营现金流0.30元。 - Ownership: controlling shareholder 江苏恒瑞医药集团有限公司; actual controller 孙飘扬; largest holder at 19 Aug 2026: 江苏恒瑞医药集团有限公司, 23.18%.
股权：控股股东：江苏恒瑞医药集团有限公司；实际控制人：孙飘扬；2026年8月19日第一大股东：江苏恒瑞医药集团有限公司，持股23.18%。 - Latest distribution: ex-date 27 May 2026, cash RMB0.20 per share.
最近一次分配：除权除息日2026年5月27日，每股现金0.20元。 - Aurelian Grade C, score 54.8 of 100, graded within a peer group of 158 companies in its industry; no rank among peers is given.
金源评级C，得分54.8（满分100），于行业同业158家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。